Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a low survival rate. Recently, new drugs that target KRAS(G12D), a common mutation in PDAC, have been developed. We studied one of these compounds, MRTX1133, and found it was specific and effective at low nanomolar concentrations in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulay, Kevin Christian Montecillo, Zhang, Xinlian, Pantazopoulou, Vasiliki, Patel, Jay, Esparza, Edgar, Pran Babu, Deepa Sheik, Ogawa, Satoshi, Weitz, Jonathan, Ng, Isabella, Mose, Evangeline S., Pu, Minya, Engle, Dannielle D., Lowy, Andrew M., Tiriac, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Priority Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502451/
https://www.ncbi.nlm.nih.gov/pubmed/37378556
http://dx.doi.org/10.1158/0008-5472.CAN-23-1313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502451/
https://www.ncbi.nlm.nih.gov/pubmed/37378556
http://dx.doi.org/10.1158/0008-5472.CAN-23-1313

Ejemplares similares